Read our latest updates & insights

Sandoz indicates it plans to conduct further studies with a target of 2018 for further submissions to the FDA.

FDA accepts Coherus BioSciences 351(k) filing for pegfilgrastim.

Teva and Celltrion announce exclusive marketing deal under which Teva will commercialise Celltrion’s biosimilar rituximab and trastuzumab products in the US and CA.

Samsung application for SB3, biosimilar trastuzumab accepted for review by EMA.

FDA approves Amgen’s biosimilar to adalimumab, Amjevita™ (adalimumab-atto), 11 months after Amgen’s application was filed.

Brenzys®(SB4)  is the first biosimilar etanercept to be approved in Canada.

Pfizer terminates its relationship with Pfenex to develop PF582, biosimilar ranibizumab.

Brenzys® (SB4) becomes the first biosimilar etanercept to be approved in Australia.

EMA accepts Mylan/Biocon application for biosimilar pegfilgrastm for review.

FDA rejects Sandoz’s application for Zioxtenzo®, biosimilar pegfilgrastim.